WO2000073421A2 - Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells - Google Patents
Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells Download PDFInfo
- Publication number
- WO2000073421A2 WO2000073421A2 PCT/US2000/040052 US0040052W WO0073421A2 WO 2000073421 A2 WO2000073421 A2 WO 2000073421A2 US 0040052 W US0040052 W US 0040052W WO 0073421 A2 WO0073421 A2 WO 0073421A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- epithelial cells
- human amniotic
- amniotic epithelial
- human
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Definitions
- This invention relates to the isolation, culture, and preservation by cryogenic techniques of human amniotic epithelial cells and for methods of treatment therefor.
- the instant invention is directed to the isolation, culture, and preservation by cryogenic techniques of human amniotic epithelial cells which can be used as a source of multipotential cells for tissue regeneration.
- amniotic membrane transplantation has been demonstrated to restore epithelialization of corneal surface in patients with both limbal stem cell deficiency (3) and persistent epithelial defects with sterile ulceration (4).
- Amniotic membranes have also been used as dressings following dermal abrasion (5), severe burns (6, 7), chronic leg ulceration (8), and for the treatment of vaginal agenesis and vaginal reconstruction after vaginectomy (9, 10).
- amniotic cells have at least multipotential, if not pluripotential, character in tissue regeneration in vivo. Aside from its uses in reconstructive surgery, amniotic cells have also demonstrated usefulness in the treatment of inborn errors of metabolism, such as Niemann-Pick disease, which involves a genetic deficiency in the lysosomal enzyme sphingomyelinase, and GM 1 - ganglosidosis.
- Scaggiante and coworkers utilized isolated human amniotic epithelial cells directly to treat Niemann-Pick patients (12), while Sakuragawa et al. transfected amniotic cells with ⁇ -galactosidase before transplantation to correct for GM., - gangliosidosis (13). Because of the reportedly low expression of histocompatibility antigens on amniotic epithelial cells (14), these cells are ideal candidates for use as carriers in gene therapy. All references cited herein are hereby incorporated by reference.
- the present invention is directed to human amniotic epithelial cells derived from placenta at delivery, and the methods for isolating, culturing, and cryopreserving them for future therapeutic uses. Additionally, the present invention is directed to methods for inducing differentiation of these multipotential cells, for assaying the cell types derived, and for manipulating the cells by gene transfection and other means for therapeutic applications, including but not limited to enzyme replacement and gene therapy, tissue regeneration and replacement, as well as burn and wound dressings.
- An object of the present invention is to describe a method for isolating pure human amniotic epithelial cells, free from contaminating fibroblasts.
- Another object of the present invention is to describe the culture of human amniotic epithelial cells.
- Another object of the present invention is to describe long-term culture of human amniotic epithelial cells on feeder cells matched or unmatched to the same donor as the epithelial cells.
- Another object of the present invention is to describe the characterization of human amniotic epithelial cells in terms of cell morphology, epithelial membrane antigen and cytokeratin staining, and gap junctional communication.
- Another object of the present invention is to describe a method for expansion of human amniotic epithelial cells.
- Another object of the present invention is to describe methods for cryopreservation of human amniotic epithelial cells. Another object of the present invention is to describe methods for reculturing of frozen amniotic epithelial cells. Another object of the present invention is to describe methods for assessing viability, proliferation potential, and longevity of human amniotic epithelial cells.
- Another object of this invention is to describe methods for establishing a stable cell line(s) from primary human amniotic epithelial cells by exposure to selected chemical carcinogens.
- Another object of this invention is to describe methods to induce differentiation of amniotic epithelial cells to cells of different lineage, as evidenced by changes in cellular antigens.
- Another object of this invention is to describe therapeutic applications for these cells including, but not limited to: a) Autologous/heterologous enzyme replacement therapy; b) Autologous/heterologous transgene carriers in gene therapy; c) Autologous/heterologous tissue regeneration/replacement therapy; d) Reconstructive treatment by surgical implantation; and e) Reconstructive treatment of tissues with products of these cells.
- Figure 1 is a phase-contrast image of amniotic epithelial cells shortly after isolation according to the procedure of Example 1.
- Figure 2 is a phase-contrast image of amniotic epithelial cells isolated according to the procedure of Example 1 after attachment of the cells to a culture dish.
- human amniotic membranes or human amniotic epithelial cells are extracted from fresh human placenta.
- the placenta is harvested immediately after delivery, washed with sterile saline, and thereafter handled under sterile conditions.
- the amniotic membrane is then separated from the chorion. This separation may be accomplished by methods known to those of skill in the art. For example, the separation may be accomplished mechanically by using tweezers to lift the amnion from the chorion and then cutting the amniotic tissue in a circle around the umbilical cord.
- the amniotic membrane itself may be cryopreserved in a cryoprotective solution comprising a medium or buffer and a cryoprotective agent.
- media are Dulbecco's Modified Eagle Medium (DMEM), Medium 199 (M199), F-12 Medium, and RPMI Medium.
- An example of a buffer is phosphate buffered saline (PBS).
- cryoprotective agents are dimethylsulfoxide (DMSO) and glycerol.
- cryoprotective solutions are: DMEM/glycerol (1 :1 ), DMEM/7.5% DMSO, M 199/7.5% DMSO, andPBS/3.5 M DMSO.
- the amniotic membrane may be treated with antibiotics such as penicillin or streptomycin prior to cryopreservation.
- Cryopreservation may be accomplished using a rapid, flash-freeze method or by more conventional controlled rate-freeze methods.
- Rapid freezing of amniotic tissue may be accomplished by placing amniotic membrane sample(s) in a freezing tube containing a cryoprotective solution and then rapidly immersing the freezing tube in liquid nitrogen.
- General slow freezing may be accomplished by placing amniotic membrane sample(s) in a freezing tube containing a cryoprotective solution and then placing the freezing tube in a -70° C freezer.
- amniotic epithelial sample(s) may be subjected to controlled rate freezing using a standard cryogenic rate controlled system.
- amniotic epithelial cells may be isolated from the amniotic membrane and then cryopreserved in a cyoprotectant solution such as the ones listed above.
- the amniotic tissue may be treated with antibiotics such as penicillin and/or streptomycin before or after digestion or both.
- the amniotic epithelial cells may be isolated from the amniotic membrane according to standard cell isolation techniques (15).
- amniotic membrane may be treated with trypsin/EDTA and/or collagenase and may be mechanically disrupted using plastic policemen. Also selective adhesion techniques may be used to eliminate mesenchymal fibroblasts. Additionally, the amniotic membrane may be treated with dispase, and the cells sheets may be treated with trypsin/EDTA.
- Human amniotic epithelial cells are characterized by round, cobblestone morphology, large nuclei, epithelial membrane antigen and cytokeratin staining, and gap junctional communication.
- the amniotic epithelial cells may be cultured in various media, such as DMEM, F-12, M199, RPMI and combinations thereof, supplemented with fetal bovine serum (FBS), whole human serum (WHS), or human umbilical cord serum collected at the time of delivery of the placenta from which the cells are extracted, or supplemented with growth factors, cytokines, hormones, vitamins, or any combination thereof.
- FBS fetal bovine serum
- WTS whole human serum
- human umbilical cord serum collected at the time of delivery of the placenta from which the cells are extracted, or supplemented with growth factors, cytokines, hormones, vitamins, or any combination thereof.
- amniotic epithelial cells may be cultured on feeder cells, such as irradiated fibroblasts, obtained from the same placenta as the amniotic epithelial cells or from other human or nonhuman sources, or in conditioned media obtained from cultures of such feeder cells, in order to obtain continued long-term culture of amniotic epithelial cells.
- feeder cells such as irradiated fibroblasts, obtained from the same placenta as the amniotic epithelial cells or from other human or nonhuman sources, or in conditioned media obtained from cultures of such feeder cells, in order to obtain continued long-term culture of amniotic epithelial cells.
- the amniotic epithelial cells may also be expanded in the presence of an agent which suppresses cellular differentiation.
- agents are well- known in the art (16).
- agents which suppress cellular differentiation include leukemia inhibitory factor (LIF) and stem cell factor.
- LIF leukemia inhibitory factor
- agents which suppress cellular differentiation include hydrocortisone, Ca 2+ , keratinocyte growth factor (KGF), TGF- ⁇ , retinoic acid, insulin, prolactin, sodium butyrate, TPA, DMSO, NMF, DMF, collagen, laminin, heparan SO 4 , androgen, estrogen, and combinations thereof may be used to induce differentiation of these amniotic epithelial cells (15).
- amniotic epithelial tissue or cells may then be subjected to rapid, flash-freezing whereby the tissue/cells are placed in a freezing tube containing a cryoprotective solution and then the tube is rapidly immersed in liquid nitrogen.
- amniotic epithelial cells may be subjected to general controlled-rate (slow) freezing.
- General slow freezing may be accomplished by placing amniotic epithelial cells in a freezing tube containing a cryoprotective solution and then placing the freezing tube in a -70° C freezer.
- the amniotic epithelial cells can be subjected to controlled rate freezing using a standard cryogenic rate controlled system.
- the amniotic membrane tissue that has been cryopreserved may be thawed and digested to obtain amniotic epithelial cells. These cells can then be cultured in the same manner as fresh amniotic epithelial cells for further use.
- amniotic epithelial cells that have been cryopreserved are thawed and recultured for further use.
- Amniotic epithelial cells thus obtained from either thawed amniotic membranes or thawed cell cultures may be cultured in various media, such as DMEM, F-12, M199, RPMI, or combinations thereof, supplemented with fetal bovine serum, whole human serum, or matched human umbilical cord serum collected at the time of delivery of the placenta from which the cells ultimately derive.
- such amniotic epithelial cells may be treated with a prepared mixture of growth factors, cytokines, hormones, and/or vitamins.
- amniotic epithelial cells may be assessed for viability, proliferation potential, and longevity using standard techniques in the art. For example, a trypan blue exclusion assay, a fluorescein diacetate uptake assay, a propidium iodide uptake assay, or other techniques known in the art may be used to assess viability. A thymidine uptake assay, an MTT cell proliferation assay, or other techniques known in the art may be used to assess proliferation. Longevity may be determined by the maximum number of population doublings in extended cultures or other techniques known in the art.
- amniotic epithelial cells derived from cryopreserved amniotic tissue or cells may be used to establish a stable cell line(s) by exposure to selected chemical carcinogens or by other techniques known in the art. Also, cells of different lineage(s) may be derived by inducing differentiation of amniotic epithelial cells as evidenced by changes in cellular antigens.
- epithelial differentiation-inducing agents are used to accomplish such differentiation, such as growth factors (for example EGF, aFGF, bFGF, PDGF, TGF- ⁇ ), hormones (including but not limited to insulin, triiodothyronine, hydrocortisone, and dexamethasone), cytokines (for example IL-1 or ⁇ , IFN- ⁇ , TFN), matrix elements (for example collagen, laminin, heparan sulfate, Matrigel), retinoic acid, transferrin, TPA, and DMSO.
- growth factors for example EGF, aFGF, bFGF, PDGF, TGF- ⁇
- hormones including but not limited to insulin, triiodothyronine, hydrocortisone, and dexamethasone
- cytokines for example IL-1 or ⁇ , IFN- ⁇ , TFN
- matrix elements for example collagen, laminin, heparan sulfate, Matri
- Identification of differentiated cells may be accomplished by staining the cells with tissue-specific antibodies according to techniques known in the art.
- the multipotentiality of the amniotic epithelial cells may also be demonstrated by their ability to form teratomas after injection into nude or severe combined immunodeficient (SCID)-beige mice, as has been demonstrated for human embryonic stem cells (2).
- SCID severe combined immunodeficient
- human amniotic epithelial cells are derived from a readily available source (placenta) which is normally discarded after birth.
- placenta readily available source
- cultured human amniotic epithelium is an ideal candidate for use in regenerative and/or reconstructive surgery, as well as for use in gene therapy.
- Amniotic epithelial cells isolated from placenta and derived from cryopreserved amniotic tissue and/or cells may be used in autologous/heterologous enzyme replacement therapy in specific conditions including, but not limited to, lysosomal storage diseases, such as Tay-Sachs, Niemann-Pick, Fabry's, Gaucher's, Hunter's, Hurier's syndrome, as well as other gangliosidoses, mucopolysaccharidoses, and glycogenoses.
- lysosomal storage diseases such as Tay-Sachs, Niemann-Pick, Fabry's, Gaucher's, Hunter's, Hurier's syndrome, as well as other gangliosidoses, mucopolysaccharidoses, and glycogenoses.
- amniotic epithelial cells isolated from placenta and derived from cryopreserved amniotic tissue and/or cells may be used as autologous/heterologous transgene carriers in gene therapy to correct inborn errors of metabolism affecting the cardiovascular, respiratory, gastrointestinal, reproductive, and nervous systems, or to treat cancer and other pathological conditions.
- Amniotic epithelial cells isolated from placenta and derived from cryopreserved amniotic tissue and/or cells also may be used in autologous/heterologous tissue regeneration/replacement therapy, including but not limited to treatment of corneal epithelial defects, cartilage repair, facial dermabrasion, burn and wound dressing for traumatic injuries of skin, mucosal membranes, tympanic membranes, intestinal linings, and neurological structures.
- Amniotic epithelial cells isolated from placenta and derived from cryopreserved amniotic tissue and/or cells also may be used in reconstructive treatment of damaged tissue by surgical implantation of cell sheets, disaggregated cells, and cells embedded in carriers for regeneration of tissues for which differentiated cells have been produced.
- Products of amniotic epithelial cells isolated from placenta and derived from cryopreserved amniotic tissue and/or cells also may be used in reconstructive treatment, either in vivo or ex vivo.
- Examples of such products include growth factors, cytokines, and other biological response modifiers.
- a human placenta was harvested and washed with sterile saline. Under sterile conditions, the amnion was separated from the chorion using tweezers to lift the amnion from the chorion. The amnion was then cut in a circle around the umbilical cord, and then cut in wedged-shape pieces radiating outward from the cord. The membrane was immediately placed in a few hundred milliliters of sterile phosphate-buffered saline withlOO lU/ml penicillin and 100ug/ml streptomycin where it was cut into small strips (approximately 2 x 2 cm) for immediate freezing or for further digestion to dissociate the cells.
- the strips of amniotic tissue prepared according to Example 1 were incubated in a few milliliters of 0.05% trypsin/ 0.53 mM EDTA for 0.5 hr at 37° C in a humidified CO 2 incubator. Then, the tissue was transferred to another culture dish containing a few milliliters of 0.03% collagenase in PBS and incubated for another 1.5 hrs in the humidified CO 2 incubator, with periodic mechanical disruption of the tissue using plastic policemen. The disaggregated amniotic tissue was then pipetted and transferred to a conical tube for further incubation in approximately 10ml collagenase in a shaking water bath.
- the cells were then pelleted and resuspended in 10 ml M 199 medium containing 10% fetal bovine serum, 2mM glutamine, and 100 lU/ml penicillin and 100 ug/ml streptomycin and placed in culture dishes.
- the cells were released from the culture for splitting using a combination of dispase at 2U/ml in medium and 0.05% trypsin/0.53 mM EDTA. Phase-contrast images of amniotic epithelial cells isolated in this manner are shown in Figures 1 and 2.
- General slow freezing was accomplished by placing vials of amniotic tissue in cryoprotective solution prepared according to Example 1 or amniotic cells prepared according to Example 2 in a foam box in a -70° C freezer. Alternatively, disaggregated amniotic cells prepared according to Example 2 were suspended in 1 ml cryoprotective solution and subjected to rate freezing.
- Cryoprotectants included: DMEM/7.5% DMSO, M199/7.5% DMSO, and DMEM/glycerol (1 :1 ).
- Controlled rate freezing was accomplished using a Forma Scientific Cryomed Freezing Chamber, Model 8026 controlled by a Cryomed Model 1010 Programmable Freezing System. Cryomed's standard Program 1 was used for controlled rate freezing. All samples were kept for long-term storage in a Forma Scientific Liquid Nitrogen Storage System (Cryoplus 7400).
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU48609/00A AU4860900A (en) | 1999-06-02 | 2000-06-01 | Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13774099P | 1999-06-02 | 1999-06-02 | |
US60/137,740 | 1999-06-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000073421A2 true WO2000073421A2 (en) | 2000-12-07 |
WO2000073421A3 WO2000073421A3 (en) | 2001-04-26 |
Family
ID=22478856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/040052 WO2000073421A2 (en) | 1999-06-02 | 2000-06-01 | Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4860900A (en) |
WO (1) | WO2000073421A2 (en) |
Cited By (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001023532A1 (en) * | 1999-09-29 | 2001-04-05 | Spyros Tsakas | Cryopreserved amniotic human cells for future therapeutic, diagnostic, genetic and others uses |
WO2003047607A1 (en) * | 2001-12-06 | 2003-06-12 | Sankyo Company, Limited | Medicinal compositions containing human amnion-origin cells |
WO2005001081A1 (en) * | 2003-06-27 | 2005-01-06 | UNIVERSITé LAVAL | Method of isolating cells from umbilical cord |
EP1497435A2 (en) * | 2002-04-19 | 2005-01-19 | University of Pittsburgh of the Commonwealth System of Higher Education | Placental derived stem cells and uses thereof |
US7045148B2 (en) | 2000-12-06 | 2006-05-16 | Anthrogenesis Corporation | Method of collecting placental stem cells |
WO2005042703A3 (en) * | 2003-10-22 | 2006-06-22 | M Of Higher Education Universi | Placental stem cells and uses thereof |
US7118845B2 (en) | 2000-06-15 | 2006-10-10 | 3M Innovative Properties Company | Multiphoton photochemical process and articles preparable thereby |
EP1775341A1 (en) * | 2004-06-28 | 2007-04-18 | National University of Corporation Hiroshima University | Method of inducing the differentiation of amnion-origin cells and utilization of the same |
WO2007046775A1 (en) | 2005-10-21 | 2007-04-26 | Cellresearch Corporation Pte Ltd | Isolation and cultivation of stem/progenitor cells from the amniotic membrane of umbilical cord and uses of cells differentiated therefrom |
GB2432166A (en) * | 2004-08-16 | 2007-05-16 | Cellres Corp Pte Ltd | Isolation of stem/progenitor cells from amniotic membrane of umbilical cord |
US7462448B2 (en) | 2002-08-02 | 2008-12-09 | Stratatech Corporation | Species specific DNA detection |
US20090238801A1 (en) * | 2006-06-28 | 2009-09-24 | University Of Medicine And Dentistry Of New Jersey | Amnion-derived stem cells and uses thereof |
EP2164953A1 (en) * | 2007-06-18 | 2010-03-24 | Children's Hospital & Research Center at Oakland | Method of isolating stem and progenitor cells from placenta |
US7700090B2 (en) | 2002-02-13 | 2010-04-20 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
EP2186407A1 (en) | 2002-02-13 | 2010-05-19 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
JP2010528055A (en) * | 2007-05-28 | 2010-08-19 | モナッシュ ユニバーシティ | Treatment of chronic lung disease |
US20100291679A1 (en) * | 2005-12-29 | 2010-11-18 | Anthrogenesis Corporation | Composition for collecting and preserving placental stem cells and methods of using the composition |
EP2314673A1 (en) | 2001-02-14 | 2011-04-27 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
EP2316463A1 (en) | 2001-02-14 | 2011-05-04 | Anthrogenesis Corporation | Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells |
US7968336B2 (en) | 2001-11-15 | 2011-06-28 | Children's Medical Center Corporation | Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof |
EP2366775A1 (en) | 2006-03-23 | 2011-09-21 | Pluristem Ltd. | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
US8048619B2 (en) | 2005-06-02 | 2011-11-01 | Stemcyte, Inc. | Method of treating a hematopoietic associated disease or disorder with plasma-depleted, but not erythrocyte-depleted cord blood compositions |
US8057789B2 (en) | 2002-02-13 | 2011-11-15 | Anthrogenesis Corporation | Placental stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
US8062837B2 (en) | 2002-02-14 | 2011-11-22 | Stemcyte, Inc. | Plasma-depleted, not erythrocyte-depleted, cord blood compositions and method of making |
US8067233B2 (en) | 2004-02-26 | 2011-11-29 | Reliance Life Science Pvt. Ltd. | Pluripotent embryonic-like stem cells derived from corneal limbus, methods of isolation and uses thereof |
EP2390311A1 (en) | 2002-04-12 | 2011-11-30 | Celgene Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US8153430B2 (en) | 2005-03-31 | 2012-04-10 | Stemnion, Inc. | Methods related to surgery |
US8187875B2 (en) | 2004-02-26 | 2012-05-29 | Reliance Life Sciences Pvt. Ltd. | Dopaminergic neurons derived from corneal limbus, methods of isolation and uses thereof |
US8187881B2 (en) | 2006-03-29 | 2012-05-29 | Stemnion, Inc. | Methods related to wound healing |
US8197804B2 (en) | 2007-04-13 | 2012-06-12 | Stemnion, Inc. | Methods for treating nervous system injury and disease |
US8221741B2 (en) | 2007-01-17 | 2012-07-17 | Marshall Vivienne S | Methods for modulating inflammatory and/or immune responses |
US8338175B2 (en) | 2006-02-24 | 2012-12-25 | Reliance Life Sciences Pvt. Ltd. | Conjunctival tissue system |
WO2013079701A2 (en) | 2011-11-30 | 2013-06-06 | University Of Bremen | Expression of mirnas in placental tissue |
US8460650B2 (en) | 2007-02-12 | 2013-06-11 | Anthrogenesis Corporation | Treatment of inflammatory diseases using placental stem cells |
US8506949B2 (en) | 2007-01-17 | 2013-08-13 | Stemnion, Inc. | Methods for modulating inflammatory and/or immune responses |
US8617535B2 (en) | 2002-11-26 | 2013-12-31 | Anthrogenesis Corporation | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
US8685390B2 (en) | 2005-03-31 | 2014-04-01 | Stemnion, Inc. | Amnion-derived cell compositions, methods of making and uses thereof |
CN103725643A (en) * | 2013-12-30 | 2014-04-16 | 厦门大学 | Method of constructing corneal endothelium of tissue engineering |
CN103966159A (en) * | 2014-02-13 | 2014-08-06 | 天津和泽干细胞科技有限公司 | Sub-totipotent stem cell of human placenta and stem cell bank construction method thereof |
US8840665B2 (en) | 2010-06-11 | 2014-09-23 | Liventa Bioscience, Inc. | Method of tendon repair with amnion and chorion constructs |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US8961617B2 (en) | 2012-03-08 | 2015-02-24 | Liventa Bioscience, Inc. | Amnion and chorion constructs and uses thereof in abdominal surgery |
US9040035B2 (en) | 2011-06-01 | 2015-05-26 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
US9078898B2 (en) | 2005-12-29 | 2015-07-14 | Anthrogenesis Corporation | Placental stem cell populations |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
EP3031909A1 (en) * | 2005-10-13 | 2016-06-15 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
EP3019186A4 (en) * | 2013-07-12 | 2017-03-29 | Patrick J. Casey | Method for the harvesting, processing, and storage of proteins from the mammalian feto-placental unit and use of such proteins in compositions and medical treatment |
US9611513B2 (en) | 2011-12-23 | 2017-04-04 | DePuy Synthes Products, Inc. | Detection of human umbilical cord tissue derived cells |
CN106566798A (en) * | 2016-11-08 | 2017-04-19 | 华南生物医药研究院 | Method for getting amniotic epithelial stem cells and kit |
US9717763B2 (en) | 2003-06-27 | 2017-08-01 | DePuy Synthes Products, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US9763983B2 (en) | 2013-02-05 | 2017-09-19 | Anthrogenesis Corporation | Natural killer cells from placenta |
US9943552B2 (en) | 2009-03-26 | 2018-04-17 | DePuy Synthes Products, Inc. | hUTC as therapy for Alzheimer's disease |
EP3345609A1 (en) | 2007-11-07 | 2018-07-11 | Anthrogenesis Corporation | Use of umbilical cord blood in the treatment of premature birth complications |
US10047345B2 (en) | 2012-02-13 | 2018-08-14 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells with FGF4 and nicotinamide |
US10104880B2 (en) | 2008-08-20 | 2018-10-23 | Celularity, Inc. | Cell composition and methods of making the same |
US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US10179900B2 (en) | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
US10494607B2 (en) | 2007-02-12 | 2019-12-03 | Celularity, Inc. | CD34+,CD45−placental stem cell-enriched cell populations |
US10531957B2 (en) | 2015-05-21 | 2020-01-14 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
US10557116B2 (en) | 2008-12-19 | 2020-02-11 | DePuy Synthes Products, Inc. | Treatment of lung and pulmonary diseases and disorders |
CN111518747A (en) * | 2020-04-30 | 2020-08-11 | 成都容医汇生物技术研究院 | Method for separating and extracting amniotic stem cells from placenta |
US10744164B2 (en) | 2003-06-27 | 2020-08-18 | DePuy Synthes Products, Inc. | Repair and regeneration of ocular tissue using postpartum-derived cells |
US10765705B2 (en) | 2014-11-24 | 2020-09-08 | Prime Merger Sub, Llc | Visco-supplement compositions, and methods of use thereof |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7875272B2 (en) | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
CA2592435C (en) | 2004-12-23 | 2017-03-28 | Ethicon, Incorporated | Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells |
PL1971681T3 (en) | 2005-12-16 | 2018-01-31 | Depuy Synthes Products Inc | Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation |
US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
US9200253B1 (en) | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
KR20210022148A (en) | 2007-09-28 | 2021-03-02 | 안트로제네시스 코포레이션 | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
AU2009316541B2 (en) | 2008-11-19 | 2015-08-06 | Celularity Inc. | Amnion derived adherent cells |
EP3284818B1 (en) | 2010-01-26 | 2022-03-09 | Celularity Inc. | Treatment of bone-related cancers using placental stem cells |
KR20230054905A (en) | 2010-04-07 | 2023-04-25 | 셀룰래리티 인코포레이티드 | Angiogenesis using placental stem cells |
ES2666746T3 (en) | 2010-07-13 | 2018-05-07 | Anthrogenesis Corporation | Methods to generate natural cytolytic lymphocytes |
US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD225440A1 (en) * | 1984-03-27 | 1985-07-31 | Adw Ddr | CELL MEDIUM BREED |
EP0333328A2 (en) * | 1988-02-17 | 1989-09-20 | Genethics Limited | Clinical developments using amniotic cells |
US4975365A (en) * | 1987-05-12 | 1990-12-04 | The John Hopkins University | Assay for measuring DNA cell repair potential |
WO1993023528A1 (en) * | 1992-05-15 | 1993-11-25 | North Carolina State University | Avian embryonic stem cells |
EP0815867A1 (en) * | 1996-01-23 | 1998-01-07 | Srl, Inc. | Cells for treating dementia |
WO1998037903A1 (en) * | 1997-02-28 | 1998-09-03 | Tseng Scheffer C G | Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries |
US6117676A (en) * | 1995-07-27 | 2000-09-12 | Srl, Inc. | Transfected human amniotic cells and method for producing a gene product |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3806189B2 (en) * | 1995-07-27 | 2006-08-09 | 株式会社エスアールエル | Methods for gene transfer into human amniotic cells and methods for preparing cells for gene therapy |
-
2000
- 2000-06-01 AU AU48609/00A patent/AU4860900A/en not_active Abandoned
- 2000-06-01 WO PCT/US2000/040052 patent/WO2000073421A2/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD225440A1 (en) * | 1984-03-27 | 1985-07-31 | Adw Ddr | CELL MEDIUM BREED |
US4975365A (en) * | 1987-05-12 | 1990-12-04 | The John Hopkins University | Assay for measuring DNA cell repair potential |
EP0333328A2 (en) * | 1988-02-17 | 1989-09-20 | Genethics Limited | Clinical developments using amniotic cells |
WO1993023528A1 (en) * | 1992-05-15 | 1993-11-25 | North Carolina State University | Avian embryonic stem cells |
US6117676A (en) * | 1995-07-27 | 2000-09-12 | Srl, Inc. | Transfected human amniotic cells and method for producing a gene product |
EP0815867A1 (en) * | 1996-01-23 | 1998-01-07 | Srl, Inc. | Cells for treating dementia |
WO1998037903A1 (en) * | 1997-02-28 | 1998-09-03 | Tseng Scheffer C G | Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries |
Non-Patent Citations (7)
Title |
---|
BURGOS H ET AL: "MAINTENANCE OF HUMAN AMNIOTIC MEMBRANES IN CULTURE" BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, vol. 88, no. 3, 1981, pages 294-300, XP000926095 ISSN: 0306-5456 * |
DATABASE WPI Section Ch, Week 199724 Derwent Publications Ltd., London, GB; Class B04, AN 1997-266482 XP002154009 & JP 09 094092 A (SRL KK), 8 April 1997 (1997-04-08) * |
KRUSE F E ET AL: "CRYOPRESERVED HUMAN AMNIOTIC MEMBRANE FOR OCULAR SURFACE RECONSTRUCTION" GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY,XX,SPRINGER VERLAG, vol. 238, no. 1, January 2000 (2000-01), pages 68-75, XP000923120 ISSN: 0721-832X * |
NCBI databases, Bethesda, MD, US PUBMED National Library of Medicine Scaggiante B et al., 1987 Pediatr. Med. Chir.,9 (1): 89-92 Graft of cryopreserved human amniotic epithelial cells in a subject with type B Niemann-Pick disease XP002154008 * |
TOHYAMA J ET AL: "CHARACTERIZATION OF HUMAN AMNIOTIC EPITHELIAL CELLS TRANSFORMED WITH ORIGIN-DEFECTIVE SV40 T-ANTIGEN GENE" TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE,JP,TOHOKU UNIVERSITY MEDICAL PRESS, SENDAI, vol. 182, 1997, pages 75-82, XP000886042 ISSN: 0040-8727 * |
UDOH Y ET AL., : "Long term viability of cryopreserved cultured epithelial grafts" BURNS, vol. 26, no. 6, September 2000 (2000-09), pages 535-542, XP000926096 * |
XUE S ET AL: "Interleukin-1beta Induces the Synthesis and Activity of Cytosolic Phospholipase A2 and the Release of Prostaglandin E2 in Human Amnion-Derived WISH Cells" PROSTAGLANDINS,US,BUTTERWORTH, STONEHAM, MA, vol. 49, no. 6, 1 June 1995 (1995-06-01), pages 351-369, XP004032305 ISSN: 0090-6980 * |
Cited By (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001023532A1 (en) * | 1999-09-29 | 2001-04-05 | Spyros Tsakas | Cryopreserved amniotic human cells for future therapeutic, diagnostic, genetic and others uses |
US7118845B2 (en) | 2000-06-15 | 2006-10-10 | 3M Innovative Properties Company | Multiphoton photochemical process and articles preparable thereby |
US7638141B2 (en) | 2000-12-06 | 2009-12-29 | Anthrogenesis Corporation | Isolated placental perfusate and placental cells isolated therefrom |
US7976836B2 (en) | 2000-12-06 | 2011-07-12 | Anthrogenesis Corporation | Treatment of stroke using placental stem cells |
US8580563B2 (en) | 2000-12-06 | 2013-11-12 | Anthrogenesis Corporation | Placental stem cells |
US7045148B2 (en) | 2000-12-06 | 2006-05-16 | Anthrogenesis Corporation | Method of collecting placental stem cells |
EP2338983A1 (en) | 2001-02-14 | 2011-06-29 | Anthrogenesis Corporation | Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells |
EP2336299A1 (en) | 2001-02-14 | 2011-06-22 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
EP3246396A1 (en) | 2001-02-14 | 2017-11-22 | Anthrogenesis Corporation | Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells |
EP2316919A1 (en) | 2001-02-14 | 2011-05-04 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
EP2316918A1 (en) | 2001-02-14 | 2011-05-04 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
US9139813B2 (en) | 2001-02-14 | 2015-09-22 | Anthrogenesis Corporation | Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells |
EP2314673A1 (en) | 2001-02-14 | 2011-04-27 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
EP2316463A1 (en) | 2001-02-14 | 2011-05-04 | Anthrogenesis Corporation | Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells |
EP2336301A1 (en) | 2001-02-14 | 2011-06-22 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
KR101132545B1 (en) * | 2001-02-14 | 2012-04-02 | 안트로제네시스 코포레이션 | Post-partum mammalian placenta, its use and placental stem cells therefrom |
EP2336300A1 (en) | 2001-02-14 | 2011-06-22 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
US7968336B2 (en) | 2001-11-15 | 2011-06-28 | Children's Medical Center Corporation | Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof |
US8021876B2 (en) | 2001-11-15 | 2011-09-20 | Children's Medical Center Corporation | Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof |
WO2003047607A1 (en) * | 2001-12-06 | 2003-06-12 | Sankyo Company, Limited | Medicinal compositions containing human amnion-origin cells |
US7700090B2 (en) | 2002-02-13 | 2010-04-20 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
EP2186407A1 (en) | 2002-02-13 | 2010-05-19 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
US8057789B2 (en) | 2002-02-13 | 2011-11-15 | Anthrogenesis Corporation | Placental stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
EP2292091A1 (en) | 2002-02-13 | 2011-03-09 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
EP2301343A1 (en) | 2002-02-13 | 2011-03-30 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
US8062837B2 (en) | 2002-02-14 | 2011-11-22 | Stemcyte, Inc. | Plasma-depleted, not erythrocyte-depleted, cord blood compositions and method of making |
EP2390311A1 (en) | 2002-04-12 | 2011-11-30 | Celgene Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
EP1497435A2 (en) * | 2002-04-19 | 2005-01-19 | University of Pittsburgh of the Commonwealth System of Higher Education | Placental derived stem cells and uses thereof |
EP1497435A4 (en) * | 2002-04-19 | 2005-07-27 | Univ Pittsburgh | Placental derived stem cells and uses thereof |
US7888496B2 (en) | 2002-08-02 | 2011-02-15 | Stratatech Corporation | Kit for species specific DNA detection |
US7462448B2 (en) | 2002-08-02 | 2008-12-09 | Stratatech Corporation | Species specific DNA detection |
US8617535B2 (en) | 2002-11-26 | 2013-12-31 | Anthrogenesis Corporation | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
WO2005001081A1 (en) * | 2003-06-27 | 2005-01-06 | UNIVERSITé LAVAL | Method of isolating cells from umbilical cord |
US11191789B2 (en) | 2003-06-27 | 2021-12-07 | DePuy Synthes Products, Inc. | Cartilage and bone repair and regeneration using postpartum-derived cells |
US11000554B2 (en) | 2003-06-27 | 2021-05-11 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of making and using the same |
US10758576B2 (en) | 2003-06-27 | 2020-09-01 | DePuy Synthes Products, Inc. | Soft tissue repair and regeneration using postpartum-derived cells and cell products |
US7939323B2 (en) | 2003-06-27 | 2011-05-10 | Universite Laval | Method of isolating cells from umbilical cord |
US10383898B2 (en) | 2003-06-27 | 2019-08-20 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of making and using the same |
US10744164B2 (en) | 2003-06-27 | 2020-08-18 | DePuy Synthes Products, Inc. | Repair and regeneration of ocular tissue using postpartum-derived cells |
US11179422B2 (en) | 2003-06-27 | 2021-11-23 | DePuy Synthes Products, Inc. | Method of differentiating umbilical cord tissue into a chondrogenic phenotype |
US9717763B2 (en) | 2003-06-27 | 2017-08-01 | DePuy Synthes Products, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US10039793B2 (en) | 2003-06-27 | 2018-08-07 | DePuy Synthes Products, Inc. | Soft tissue repair and regeneration using postpartum-derived cells and cell products |
US10500234B2 (en) | 2003-06-27 | 2019-12-10 | DePuy Synthes Products, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US10220059B2 (en) | 2003-06-27 | 2019-03-05 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of making and using the same |
US10195233B2 (en) | 2003-06-27 | 2019-02-05 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of making and using the same |
WO2005042703A3 (en) * | 2003-10-22 | 2006-06-22 | M Of Higher Education Universi | Placental stem cells and uses thereof |
US8187875B2 (en) | 2004-02-26 | 2012-05-29 | Reliance Life Sciences Pvt. Ltd. | Dopaminergic neurons derived from corneal limbus, methods of isolation and uses thereof |
US8067233B2 (en) | 2004-02-26 | 2011-11-29 | Reliance Life Science Pvt. Ltd. | Pluripotent embryonic-like stem cells derived from corneal limbus, methods of isolation and uses thereof |
EP1775341A4 (en) * | 2004-06-28 | 2009-06-03 | Nat University Of Corp Hiroshi | Method of inducing the differentiation of amnion-origin cells and utilization of the same |
EP1775341A1 (en) * | 2004-06-28 | 2007-04-18 | National University of Corporation Hiroshima University | Method of inducing the differentiation of amnion-origin cells and utilization of the same |
US9737568B2 (en) | 2004-08-16 | 2017-08-22 | Cellresearch Corporation Pte Ltd | Isolation, cultivation and uses of stem/progenitor cells |
US10363275B2 (en) | 2004-08-16 | 2019-07-30 | Cellresearch Corporation Pte Ltd | Isolation, cultivation and uses of stem/progenitor cells |
US9085755B2 (en) | 2004-08-16 | 2015-07-21 | Cellresearch Corporation Pte Ltd. | Isolation, cultivation and uses of stem/progenitor cells |
GB2432166A (en) * | 2004-08-16 | 2007-05-16 | Cellres Corp Pte Ltd | Isolation of stem/progenitor cells from amniotic membrane of umbilical cord |
GB2432166B (en) * | 2004-08-16 | 2008-01-02 | Cellres Corp Pte Ltd | Isolation of stem/progenitor cells from amniotic membrane of umbilical cord |
US8709402B2 (en) | 2005-03-31 | 2014-04-29 | Stemnion, Inc. | Amnion-derived cells, methods of making and uses thereof |
US8153430B2 (en) | 2005-03-31 | 2012-04-10 | Stemnion, Inc. | Methods related to surgery |
US8877181B2 (en) | 2005-03-31 | 2014-11-04 | Stemnion, Inc. | Amnion-derived cells, methods of making and uses thereof |
US8741646B2 (en) | 2005-03-31 | 2014-06-03 | Stemnion, Inc. | Amnion-derived cell compositions, methods of making and uses thereof |
US8685390B2 (en) | 2005-03-31 | 2014-04-01 | Stemnion, Inc. | Amnion-derived cell compositions, methods of making and uses thereof |
US8048619B2 (en) | 2005-06-02 | 2011-11-01 | Stemcyte, Inc. | Method of treating a hematopoietic associated disease or disorder with plasma-depleted, but not erythrocyte-depleted cord blood compositions |
EP3031909A1 (en) * | 2005-10-13 | 2016-06-15 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
CN103555655A (en) * | 2005-10-21 | 2014-02-05 | 细胞研究私人有限公司 | Isolation and cultivation of stem/progenitor cells from the amniotic membrane of umbilical cord and uses of cells differentiated therefrom |
CN103555655B (en) * | 2005-10-21 | 2018-02-27 | 细胞研究私人有限公司 | The application of ancestral cells and its cell of differentiation is separated and cultivated from umbilical cord amniotic membrane |
US8287854B2 (en) | 2005-10-21 | 2012-10-16 | Cellresearch Corporation Pte Ltd | Skin equivalents derived from umbilical cord mesenchymal stem/progenitor cells and umbilical cord epithelial stem/progenitor cells |
US10066209B2 (en) | 2005-10-21 | 2018-09-04 | Cellresearch Corporation Pte Ltd. | Isolation and cultivation of stem/progenitor cells from the amniotic membrane of umbilical cord and uses of cells differentiated therefrom |
WO2007046775A1 (en) | 2005-10-21 | 2007-04-26 | Cellresearch Corporation Pte Ltd | Isolation and cultivation of stem/progenitor cells from the amniotic membrane of umbilical cord and uses of cells differentiated therefrom |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
US9078898B2 (en) | 2005-12-29 | 2015-07-14 | Anthrogenesis Corporation | Placental stem cell populations |
US20100291679A1 (en) * | 2005-12-29 | 2010-11-18 | Anthrogenesis Corporation | Composition for collecting and preserving placental stem cells and methods of using the composition |
US10383897B2 (en) | 2005-12-29 | 2019-08-20 | Celularity, Inc. | Placental stem cell populations |
US8455250B2 (en) | 2005-12-29 | 2013-06-04 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
US9725694B2 (en) * | 2005-12-29 | 2017-08-08 | Anthrogenesis Corporation | Composition for collecting and preserving placental stem cells and methods of using the composition |
EP2412801A1 (en) | 2005-12-29 | 2012-02-01 | Anthrogenesis Corporation | Co-Culture of placental stem cells and stem cells from a second source |
US8338175B2 (en) | 2006-02-24 | 2012-12-25 | Reliance Life Sciences Pvt. Ltd. | Conjunctival tissue system |
EP2366775A1 (en) | 2006-03-23 | 2011-09-21 | Pluristem Ltd. | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
EP3091071A1 (en) | 2006-03-23 | 2016-11-09 | Pluristem Ltd. | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
EP2626417A1 (en) | 2006-03-23 | 2013-08-14 | Pluristem Ltd. | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
EP2548951A1 (en) | 2006-03-23 | 2013-01-23 | Pluristem Ltd. | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
US8796025B2 (en) | 2006-03-29 | 2014-08-05 | Stemnion, Inc. | Methods Related to Wound Healing |
US8871198B2 (en) | 2006-03-29 | 2014-10-28 | Stemnion, Inc. | Methods related to wound healing |
US8187881B2 (en) | 2006-03-29 | 2012-05-29 | Stemnion, Inc. | Methods related to wound healing |
US10407663B2 (en) | 2006-06-28 | 2019-09-10 | Rutgers, The State University Of New Jersey | Obtaining multipotent amnion-derived stem cell (ADSC) from amniotic membrane tissue without enzymatic digestion |
US10066202B2 (en) | 2006-06-28 | 2018-09-04 | Rutgers, The State University Of New Jersey | Method of cryopreserving an amniotic membrane of a placenta tissue sample |
US20090238801A1 (en) * | 2006-06-28 | 2009-09-24 | University Of Medicine And Dentistry Of New Jersey | Amnion-derived stem cells and uses thereof |
EP2089510B1 (en) * | 2006-06-28 | 2021-02-24 | The University of Medicine and Dentistry of New Jersey | Amnion-derived stem cells and uses thereof |
US8980630B2 (en) * | 2006-06-28 | 2015-03-17 | Rutgers, The State University Of New Jersey | Obtaining multipotent amnion-derived stem cell (ADSC) from amniotic membrane tissue without enzymatic digestion |
US8221741B2 (en) | 2007-01-17 | 2012-07-17 | Marshall Vivienne S | Methods for modulating inflammatory and/or immune responses |
US9173908B2 (en) | 2007-01-17 | 2015-11-03 | Stemnion, Inc. | Methods for modulating immune responses |
US8506949B2 (en) | 2007-01-17 | 2013-08-13 | Stemnion, Inc. | Methods for modulating inflammatory and/or immune responses |
US8460650B2 (en) | 2007-02-12 | 2013-06-11 | Anthrogenesis Corporation | Treatment of inflammatory diseases using placental stem cells |
US10494607B2 (en) | 2007-02-12 | 2019-12-03 | Celularity, Inc. | CD34+,CD45−placental stem cell-enriched cell populations |
US8916146B2 (en) | 2007-02-12 | 2014-12-23 | Anthrogenesis Corporation | Treatment of inflammatory diseases using placental stem cells |
US8197804B2 (en) | 2007-04-13 | 2012-06-12 | Stemnion, Inc. | Methods for treating nervous system injury and disease |
US10286015B2 (en) | 2007-04-13 | 2019-05-14 | Noveome Biotherapeutics, Inc. | Methods for treating traumatic brain injury with amnion-derived cellular cytokine solution (ACCS) or amnion-derived multipotent progenitor (AMP) cells |
JP2010528055A (en) * | 2007-05-28 | 2010-08-19 | モナッシュ ユニバーシティ | Treatment of chronic lung disease |
EP2164953A1 (en) * | 2007-06-18 | 2010-03-24 | Children's Hospital & Research Center at Oakland | Method of isolating stem and progenitor cells from placenta |
US8273526B2 (en) | 2007-06-18 | 2012-09-25 | Children's Hospital & Research Center At Oakland | Method of isolating stem and progenitor cells from placenta |
EP2164953A4 (en) * | 2007-06-18 | 2010-06-30 | Childrens Hosp & Res Ct Oak | Method of isolating stem and progenitor cells from placenta |
EP3345609A1 (en) | 2007-11-07 | 2018-07-11 | Anthrogenesis Corporation | Use of umbilical cord blood in the treatment of premature birth complications |
US10104880B2 (en) | 2008-08-20 | 2018-10-23 | Celularity, Inc. | Cell composition and methods of making the same |
US10179900B2 (en) | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
US10557116B2 (en) | 2008-12-19 | 2020-02-11 | DePuy Synthes Products, Inc. | Treatment of lung and pulmonary diseases and disorders |
US9943552B2 (en) | 2009-03-26 | 2018-04-17 | DePuy Synthes Products, Inc. | hUTC as therapy for Alzheimer's disease |
US8647617B2 (en) | 2009-07-13 | 2014-02-11 | Stemnion, Inc. | Methods for modulating inflammatory and/or immune responses |
US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US11305035B2 (en) | 2010-05-14 | 2022-04-19 | Musculoskeletal Transplant Foundatiaon | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US8840665B2 (en) | 2010-06-11 | 2014-09-23 | Liventa Bioscience, Inc. | Method of tendon repair with amnion and chorion constructs |
US11090339B2 (en) | 2011-06-01 | 2021-08-17 | Celularity Inc. | Treatment of pain using placental stem cells |
US9040035B2 (en) | 2011-06-01 | 2015-05-26 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
WO2013079701A2 (en) | 2011-11-30 | 2013-06-06 | University Of Bremen | Expression of mirnas in placental tissue |
EP4349343A2 (en) | 2011-11-30 | 2024-04-10 | Jörn Bullerdiek | Expression of mirnas in placental tissue |
US9611513B2 (en) | 2011-12-23 | 2017-04-04 | DePuy Synthes Products, Inc. | Detection of human umbilical cord tissue derived cells |
US10724105B2 (en) | 2011-12-23 | 2020-07-28 | DePuy Synthes Products, Inc. | Detection of human umbilical cord tissue-derived cells |
US10047345B2 (en) | 2012-02-13 | 2018-08-14 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells with FGF4 and nicotinamide |
US8961617B2 (en) | 2012-03-08 | 2015-02-24 | Liventa Bioscience, Inc. | Amnion and chorion constructs and uses thereof in abdominal surgery |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US9763983B2 (en) | 2013-02-05 | 2017-09-19 | Anthrogenesis Corporation | Natural killer cells from placenta |
EP3019186A4 (en) * | 2013-07-12 | 2017-03-29 | Patrick J. Casey | Method for the harvesting, processing, and storage of proteins from the mammalian feto-placental unit and use of such proteins in compositions and medical treatment |
CN103725643A (en) * | 2013-12-30 | 2014-04-16 | 厦门大学 | Method of constructing corneal endothelium of tissue engineering |
CN103966159A (en) * | 2014-02-13 | 2014-08-06 | 天津和泽干细胞科技有限公司 | Sub-totipotent stem cell of human placenta and stem cell bank construction method thereof |
CN103966159B (en) * | 2014-02-13 | 2015-08-05 | 天津和泽干细胞科技有限公司 | Human plactnta Subaerial blue green algae and stem cell bank construction process thereof |
US10765705B2 (en) | 2014-11-24 | 2020-09-08 | Prime Merger Sub, Llc | Visco-supplement compositions, and methods of use thereof |
US11896623B1 (en) | 2014-11-24 | 2024-02-13 | Prime Merger Sub, Llc | Visco-supplement compositions, and methods of use thereof |
US10531957B2 (en) | 2015-05-21 | 2020-01-14 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
US11596517B2 (en) | 2015-05-21 | 2023-03-07 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
CN106566798A (en) * | 2016-11-08 | 2017-04-19 | 华南生物医药研究院 | Method for getting amniotic epithelial stem cells and kit |
CN111518747A (en) * | 2020-04-30 | 2020-08-11 | 成都容医汇生物技术研究院 | Method for separating and extracting amniotic stem cells from placenta |
Also Published As
Publication number | Publication date |
---|---|
WO2000073421A3 (en) | 2001-04-26 |
AU4860900A (en) | 2000-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000073421A2 (en) | Methods of isolation, cryopreservation, and therapeutic use of human amniotic epithelial cells | |
US20200188446A1 (en) | Renovation and Repopulation of Decellularized Tissues and Cadaveric Organs by Stem Cells | |
Kruse et al. | Cryopreserved human amniotic membrane for ocular surface reconstruction | |
US20200048603A1 (en) | Cd34+,cd45- placental stem cell-enriched cell populations | |
KR20070015519A (en) | Biological tissue sheet, method of forming the same and transplantation method by using the sheet | |
AU2002243980A1 (en) | Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells | |
US20060228339A1 (en) | Methods of preparing transplantable product for treatment of skin defects | |
EP2368974A1 (en) | Methods for isolating mesenchymal stem cells from embryos of human or animals and extracting secretion substances thereof | |
JPH02200178A (en) | Product of proliferated pancreas endocrine cell and method of production thereof | |
WO2009042201A1 (en) | Angiogenic cells from human placental perfusate | |
EP1733026A2 (en) | Tissue system with undifferentiated stem cells derived from corneal limbus | |
Galindo et al. | Expression of ΔNp63 in response to phorbol ester in human limbal epithelial cells expanded on intact human amniotic membrane | |
US9211306B2 (en) | Cellular therapeutic agent for incontinence or urine comprising stem cells originated from decidua or adipose | |
Compton et al. | Melanocytes in cultured epithelial grafts are depleted with serial subcultivation and cryopreservation: implications for clinical outcome | |
Nejat-Dehkordi et al. | Embryo co-culture with bovine amniotic membrane stem cells can enhance the cryo-survival of IVF-derived bovine blastocysts comparable with co-culture with bovine oviduct epithelial cells | |
Lin et al. | Following the fate of murine epidermal stem cells in a syngeneic dermal equivalent in vivo | |
CN117778321A (en) | Isolation and expansion of primary corneal stromal cells in humans using corneal lenses obtained during SMILE surgery | |
Yoshino et al. | The characterization of human lacrimal gland acinar and ductal epithelia in various culture systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |